Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the phase 2 results of the ARTEMIS-UC trial, and the potential of PRA023 (anti-TL1A) for the treatment of ulcerative colitis

Ticker(s): RXDX

Who's the expert?

Institution: NYU

Assistant Professor of Medicine in the Division of Gastroenterology at NYU Grossman School of Medicine & gastroenterologist at the IBD Center at NYU Langone Health.
Manages 350 unique patients with Crohn's disease annually.
Extremely familiar with study data and was PI on trials from Vedanta and Gilead in UC.

Interview Goal

To discuss the results of the ARTEMIS-UC trial and get an idea how well it is likely to translate into phase 3, and how it may fit into the UC landscape commercially.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.